Value20242025TTMSelling/general/admin expenses23.1 M22.28 M22.18 MResearch & development70.47 M74.54 M70.7 MOperating income-93.53 M-96.82 M-92.88 MNon-Operating Income, Total24.84 M-44.14 M-15.12 MInterest expense, net of interest capitalized———Non-Operating Income, excl. Interest Expenses24.88 M-44.09 M-15.07 MUnusual income/expense-47 K-53 K—Pretax income-68.69 M-140.95 M-108 MEquity in earnings———Taxes00—Non-controlling/minority interest———After tax other income/expense———Net income before discontinued operations-68.69 M-140.95 M-108 MDiscontinued operations———Net income-68.69 M-140.95 M-108 MDilution adjustment0——Preferred dividends1.74 M——Diluted net income available to common stockholders-70.43 M-140.95 M-108 MBasic earnings per share (Basic EPS)-1.62-1.86-1.31Diluted earnings per share (Diluted EPS)-1.62-1.86-1.31Average basic shares outstanding43.54 M75.82 M—Diluted shares outstanding43.54 M75.82 M—EBITDA-92.85 M-95.69 M—EBIT-93.53 M-96.82 M—Cost of revenue50 K0—Other cost of goods sold———Depreciation & amortization (cash flow)677 K1.13 M1.12 M
Fractyl Health, Inc. - Common Stock
Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1.